News
-
-
-
COMMUNIQUÉ DE PRESSE
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
FSD Pharma submits a clinical trial application for Lucid-21-302, a neuroprotective compound for multiple sclerosis treatment, to an Australian ethics review committee -
-
-
COMMUNIQUÉ DE PRESSE
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
FSD Pharma partners with ASPI to conduct a study on unbuzzd™, a supplement for alcohol intoxication. The study aims to assess safety and efficacy in healthy volunteers -
-
-
-
